Fixed-Dose Combinations
A combination formulation of rifampin, isoniazid and pyrazinamide (Rifater) is approved by the FDA for the initial 2 months of daily anti-tuberculosis therapy. A combination of rifampin and isoniazid (Rifamate) has been available in the US since 1975. Fixed-dose combinations may be particularly useful for patients self-administering their therapy.